Why Only 20% of Eligible Patients Get Cell Therapy & What Needs To Change I Matt Hewitt & Jeff Holder

Matt Hewitt (Charles River) and Jeff Holder (LEK) explain why only 20% of eligible patients get cell therapy and what’s blocking CAR-T access.

Matt Hewitt (Charles River) and Jeff Holder (LEK) explain why only 20% of eligible patients get cell therapy and what’s blocking CAR-T access.
Get a free quarterly briefing: four pages on what life-sciences operators are actually saying about Biosecure, AI hype vs. substance, and the $50,000 cell-therapy question. Ten minutes, in your inbox.